Audentes Therapeutics, Inc. announced the promotion of Natalie Holles from Senior Vice President and Chief Operating Officer to President and Chief Operating Officer. In this new role, Ms. Holles will oversee the day-to-day operations of the company, including research, development, manufacturing, program management and corporate development. Ms. Holles joined Audentes in 2015, bringing 15 years of corporate development, strategic planning, and commercial experience gained in a range of therapeutic areas and with a focus on rare diseases. Prior to joining Audentes, Ms. Holles served as Senior Vice President, Corporate Development at Hyperion Therapeutics, Inc. from 2013 through its acquisition by Horizon Pharma, plc in May 2015.